Last week, after defeating about a dozen amendments, the Senate Finance Committee approved a bill that would allow, but not require, the administration to interfere in Medicare drug price negotiations between private drug plans and the pharmaceutical companies. Chairman Max Baucus (D-Mont.) was criticized by members of his own party for offering what they said was a watered-down … [Read more...] about Unhealthy, slippery slope
Slippery Slope
After defeating about a dozen amendments, the Senate Finance Committee last night approved a bill that would allow, but not require, the administration to interfere in drug price negotiations between private drug plans and the pharmaceutical companies. Chairman Max Baucus (D-MT) was criticized by members of his own party for offering what they said was a watered-down version of the bill that … [Read more...] about Slippery Slope
Joel White Joins Galen Institute as Senior Fellow
The Galen Institute is pleased to announce that Joel White, former staff director of the House Ways and Means Health Subcommittee, is joining the institute as a visiting senior fellow. In his new role, Joel will advance the institute?s work on public policy in the key areas of health and tax issues and will promote free-market ideas for health reform through speeches and writing. Joel is … [Read more...] about Joel White Joins Galen Institute as Senior Fellow
The Good News
We are so very pleased to announce that Joel White, former staff director of the House Ways and Means Health Subcommittee, is joining the Galen Institute as a visiting senior fellow. In his new role, Joel will advance our work on the key areas of health and tax policy and will promote free-market ideas for health reform through speeches and writing. Joel is president of JCWhite Consulting, a firm … [Read more...] about The Good News
Joel White Joins Galen Institute as Senior Fellow
The Galen Institute is pleased to announce that Joel White, former staff director of the House Ways and Means Health Subcommittee, is joining the institute as a visiting senior fellow. In his new role, Joel will advance the institute?s work on public policy in the key areas of health and tax issues and will promote free-market ideas for health reform through speeches and writing. Joel is … [Read more...] about Joel White Joins Galen Institute as Senior Fellow
The Consequences of "Negotiation"
Within the next few weeks, the Senate is expected to vote on whether to allow the federal government to negotiate prices for prescription drugs offered through the new Medicare drug program. The House already has passed a similar bill that advocates say would bring lower drug prices to seniors. That sounds nice, doesn't it? Who in the Senate could possibly be opposed to "negotiations" and "lower … [Read more...] about The Consequences of "Negotiation"
The Consequences of “Negotiation”
Within the next few weeks, the Senate is expected to vote on whether to allow the federal government to negotiate prices for prescription drugs offered through the new Medicare drug program. The House already has passed a similar bill that advocates say would bring lower drug prices to seniors. That sounds nice, doesn't it? Who in the Senate could possibly be opposed to "negotiations" and … [Read more...] about The Consequences of “Negotiation”
Toward Free-Market Health Care
Our health care sector must change to meet the challenges of a 21st century economy. Consumers, not just in the United States but in all developed countries, are demanding a much greater role in decisions involving their health care. People can find on the Internet a wealth of information about diseases, diagnoses, and treatment options, but all too often, they must fight bureaucracies and … [Read more...] about Toward Free-Market Health Care